SCHEMBL15260737

SCHEMBL15260737

COc1ccc(Cn2cc3c(n2)C(Cl)(C(F)(F)F)CCc2sc(NC(=O)OC(C)(C)C)nc2-3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
TP53 P04637 5/20 0.41
RXFP1 Q9HBX9 2/20 0.38
ALDH1A1 P00352 5/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HPGD P15428 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
RAB9A P51151 2/20 0.37
TDP2 O95551 2/20 0.37
APAF1 O14727 1/20 0.37
CASP3 P42574 1/20 0.37
BLM P54132 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15261246 0.91 MAPT (0.39) MAPTSMN1; SMN2TP53RXFP1ALDH1A1
SCHEMBL15261239 0.88 MAPT (0.40) MAPTSMN1; SMN2TP53RXFP1ALDH1A1
SCHEMBL366960 0.83 MAPT (0.44) MAPTSMN1; SMN2TP53RXFP1ALDH1A1
SCHEMBL15261475 0.82 RXFP1 (0.42) MAPTSMN1; SMN2TP53RXFP1ALDH1A1
SCHEMBL15260678 0.82 RXFP1 (0.41) MAPTSMN1; SMN2TP53RXFP1ALDH1A1
SCHEMBL369225 0.79 MAPT (0.45) MAPTSMN1; SMN2TP53RXFP1ALDH1A1
SCHEMBL15261025 0.76 ACHE (0.40) MAPTRXFP1ALDH1A1KDM4EHPGD
SCHEMBL6837270 0.75 LCK (0.38) MAPTSMN1; SMN2RXFP1ALDH1A1KDM4E
SCHEMBL369851 0.74 GSK3A (0.40) MAPTRXFP1ALDH1A1MEN1KMT2A
SCHEMBL369206 0.74 GSK3B (0.40) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 MAPT 1266/4885SMN1; SMN2 2061/4885TP53 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.